Loading...
By Kelly Young
Edited by Susan Sadoughi, MD
Valsartan contaminated with N-nitrosodimethylamine (NDMA), a probable carcinogen, has not led to a short-term increase in new cancers, according to a retrospective study in Denmark published in The BMJ. Since July, over half the valsartan products on the U.S. market have been recalled because of the NDMA impurity, thought to be introduced during manufacturing.
Using Danish registries, researchers compared roughly 3500 patients who filled prescriptions for possibly NDMA-contaminated valsartan between 2012 and 2018 with 3600 who used valsartan thought to be NDMA-free. During a median follow-up of roughly 5 years, exposure to NDMA-contaminated valsartan was not associated with increased risk for incident cancer compared with noncontaminated valsartan.
The researchers note that the daily NDMA exposure through valsartan is about 30 times lower than the lowest dose that led to liver cancer in rat studies.
Editorialists caution: "This study alone cannot dispel doubts about the potential risk for patients in the longer term."
Comment
LINK(S):
The BMJ article (Free)
The BMJ editorial (Subscription required)
FDA statement on valsartan recall (Free)
Background: Physician's First Watch early coverage of valsartan recall (Free)